(Q44282947)

1 December 2017

title

Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection (English)

1 reference

1 December 2017

0 references

Isada CM

1

1 reference

1 December 2017

Yen-Lieberman B

2

1 reference

1 December 2017

Lurain NS

3

1 reference

1 December 2017

Schilz R

4

1 reference

1 December 2017

Kohn D

5

1 reference

1 December 2017

Longworth DL

6

1 reference

1 December 2017

Taege AJ

7

1 reference

1 December 2017

Mossad SB

8

1 reference

1 December 2017

Maurer J

9

1 reference

1 December 2017

Flechner SM

10

1 reference

1 December 2017

Mawhorter SD

11

1 reference

1 December 2017

Braun W

12

1 reference

1 December 2017

Gordon SM

13

1 reference

1 December 2017

Schmitt SK

14

1 reference

1 December 2017

Goldman M

15

1 reference

1 December 2017

Long J

16

1 reference

1 December 2017

Haug M

17

1 reference

1 December 2017

Avery RK

18

1 reference

1 December 2017

publication date

1 December 2002

1 reference

Transplant Infectious Disease

1 December 2017

published in

1 reference

1 December 2017

volume

4

1 reference

1 December 2017

issue

4

1 reference

1 December 2017

page(s)

189-194

1 reference

Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

Ganciclovir resistance: a matter of time and titre

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

Development of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant recipient.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

Cytomegalovirus (CMV) resistance to antivirals

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

Multicenter comparison of the digene hybrid capture CMV DNA assay (version 2.0), the pp65 antigenemia assay, and cell culture for detection of cytomegalovirus viremia.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2002.T01-1-02008.X

7 January 2021

10.1034/J.1399-3062.2002.T01-1-02008.X

Identifiers

DOI

1 reference

1 December 2017

1 reference